Fiasp Penfill is a rapid-acting insulin for the treatment of diabetes mellitus [1]. It is a formulation of insulin aspart, designed to lower blood glucose levels [2].
How quickly does Fiasp start working?
Fiasp begins to work faster than other mealtime insulin analogs [1]. It is intended for use at the start of a meal or within 20 minutes after starting a meal [1].
What is the difference between Fiasp and other insulin aspart products?
Fiasp contains insulin aspart along with niacinamide (vitamin B3) [2]. This combination allows Fiasp to be absorbed more rapidly from the injection site and reach the bloodstream faster compared to other insulin aspart formulations [1].
When does the patent for Fiasp expire?
The patent landscape for Fiasp can be complex, involving patents on the drug itself, its formulation, and delivery devices. Information on specific patent expiry dates for Fiasp can be found on resources like DrugPatentWatch.com [3].
Who manufactures Fiasp?
Fiasp is developed and manufactured by Novo Nordisk [1].
What are the potential risks or side effects of Fiasp?
As with all insulins, the most common side effect of Fiasp is hypoglycemia, or low blood sugar [1]. Other potential side effects can include injection site reactions and allergic reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider.